This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

About the NKI

The Netherlands Cancer Institute was established on October 10, 1913. The founders, Rotgans, professor of Surgery, De Bussy, publisher, and De Vries, professor of Pathology, wanted to create a cancer institute 'where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied'. They bought a house on one of the canals in Amsterdam and named it the 'Antoni van Leeuwenhoek Huis', after the famous Dutch microscopist. The clinic had room for 17 patients, while the laboratory could accommodate 8 to 10 scientists.

Nowadays, The Netherlands Cancer Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiotion units for radiotherapy. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.


  • 17Sep 2019

    Thesis defense Willeke Ros

    While some immunotherapies already help cancer patients, many more of this type of drugs that are aimed at encouraging the immune system to fight cancer are being developed. During her PhD research Willeke Ros studied the efficacy and safety of several of those medicines in the first patients. She also investigated whether the already registered immunotherapy pembrolizumab could be effective against rare tumors.

    Read More
  • 12Sep 2019

    Research into the quality of life in cancer patients in the palliative care phase: Lonneke van de Poll on the eQuiPe study

    Strange as this may sound, very little is known about the quality of life of terminal cancer patients in the palliative care phase. Medical practitioners are often uncertain of what they can still offer such patients, their relatives and carers. The eQuiPe study is going to change this state of affairs.

    Read More
  • 05Sep 2019

    Thesis defense Marie-Rose Crombag anti-cancer drugs in the elderly

    A priori dose reductions solely based on age are not advisable and may threaten optimal treatment outcome. This is what Marie-Rose Crombag concludes from her PhD research that she did in the NKI. On 5 September, she defended her thesis at Utrecht University. Her promotor was Jos Beijnen and het co-promotor was Alwin Huitema.

    Read More
  • 04Sep 2019

    Breast cancer is coming within reach of immunotherapy

    Breast cancer has not hitherto been at the forefront of immunotherapy treatment. At the 17th Bossche Mamma Congress, Dr. Marleen Kok (of The Netherlands Cancer Institute) explains why, and how immunotherapy is gradually gaining traction in the treatment of breast cancer.

    Read More

Board of Directors

Overview boards and commissions


Internal procedures

The NKI has adopted several regulations and procedures which help us organize our research along national and international standards. The most important regulations and procedures can be found here.

Read more


Technology Transfer Office

The NKI has a mission to beat cancer and performs world-beating research to increase our understanding of this disease. The knowledge that is gained in this way sometimes opens avenues for development of e.g. novel treatments or new diagnostic tests. To achieve its mission, NKI actively collaborates with private companies that have the knowledge and the means to develop products based on research results obtained at our institution.

Go to the site of the Technology Transfer Office

Scientific Annual Reports (SAR)



Group Leaders51
PhD Students187


  • Silhoutten



  • Silhoutten



  • Horloge



  • Silhoutten



  • Bed



Key Figures Research

Publications in 2016 805
Total impact of publications in 2014 3935
Avarage impact of publications 2014 6.8

Key Figures Research

Number of divisions 15
Number of Reseach groups 51
Share this page